OmniAb (OABI) Non-Current Deffered Revenue (2021 - 2026)
OmniAb (OABI) reported Non-Current Deffered Revenue of $369000.0 for Q1 2026, up 778.57% quarter-over-quarter from $42000.0 in Q2 2025.
OmniAb (OABI) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Non-Current Deffered Revenue data on file, last reported at $369000.0 in Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $369000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $369000.0 (changed N/A YoY), and the FY2024 annual result was $117000.0, down 86.43% from the prior year.
- Non-Current Deffered Revenue climbed to $369000.0 in Q1 2026 per OABI's latest filing, from $42000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $8.0 million in Q1 2022 and troughed at $41000.0 in Q3 2024.
- A 5-year average of $2.5 million and a median of $1.4 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue plunged 97.93% in 2024, then sank 41.67% in 2025.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $4.3 million in 2022, then tumbled by 80.07% to $862000.0 in 2023, then slumped by 86.43% to $117000.0 in 2024, then plunged by 64.1% to $42000.0 in 2025, then jumped by 778.57% to $369000.0 in 2026.
- Business Quant data shows OABI's Non-Current Deffered Revenue at $369000.0 in Q1 2026, $42000.0 in Q2 2025, and $117000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 369,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 369,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Dec 31, 2024 | 117,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 72,000.00 |
| Mar 31, 2024 | 279,000.00 |
| Dec 31, 2023 | 862,000.00 |
| Sep 30, 2023 | 1.95 Mn |
| Jun 30, 2023 | 3.48 Mn |
| Mar 31, 2023 | 3.02 Mn |
| Dec 31, 2022 | 4.33 Mn |
| Sep 30, 2022 | 4.03 Mn |
| Jun 30, 2022 | 8.05 Mn |
| Mar 31, 2022 | 8.05 Mn |
| Dec 31, 2021 | 9.23 Mn |
| Sep 30, 2021 | 8.05 Mn |